Quidel Co. (NASDAQ:QDEL) Director Jack W. Schuler sold 4,000 shares of Quidel stock in a transaction dated Friday, January 5th. The stock was sold at an average price of $47.02, for a total transaction of $188,080.00. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

Quidel Co. (QDEL) opened at $45.90 on Thursday. The company has a debt-to-equity ratio of 0.70, a current ratio of 6.28 and a quick ratio of 5.68. The firm has a market cap of $1,560.00, a P/E ratio of -286.88, a PEG ratio of 1.51 and a beta of 1.15. Quidel Co. has a 52-week low of $18.25 and a 52-week high of $47.60.

Quidel (NASDAQ:QDEL) last posted its quarterly earnings data on Wednesday, November 1st. The company reported ($0.16) earnings per share for the quarter, missing analysts’ consensus estimates of $0.05 by ($0.21). The firm had revenue of $50.89 million during the quarter, compared to analyst estimates of $50.47 million. Quidel had a negative net margin of 2.33% and a negative return on equity of 2.36%. The business’s quarterly revenue was up 3.1% on a year-over-year basis. During the same period in the prior year, the firm earned $0.10 EPS. analysts forecast that Quidel Co. will post -0.23 EPS for the current year.

A number of equities analysts have issued reports on QDEL shares. Piper Jaffray Companies upgraded shares of Quidel from a “neutral” rating to an “overweight” rating and lifted their target price for the stock from $35.00 to $50.00 in a research report on Tuesday, September 19th. Raymond James Financial restated a “buy” rating and set a $47.00 target price (up previously from $41.00) on shares of Quidel in a research report on Tuesday, September 19th. Barclays restated a “buy” rating and set a $45.00 target price (up previously from $39.00) on shares of Quidel in a research report on Tuesday, September 19th. Canaccord Genuity restated a “buy” rating and set a $48.00 target price (up previously from $42.00) on shares of Quidel in a research report on Tuesday, September 19th. Finally, Zacks Investment Research upgraded shares of Quidel from a “strong sell” rating to a “hold” rating in a research report on Wednesday, September 27th. One research analyst has rated the stock with a sell rating and seven have given a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus price target of $50.00.

Large investors have recently bought and sold shares of the company. Acrospire Investment Management LLC raised its position in shares of Quidel by 42.2% in the second quarter. Acrospire Investment Management LLC now owns 3,678 shares of the company’s stock valued at $100,000 after buying an additional 1,091 shares during the last quarter. Great West Life Assurance Co. Can raised its position in shares of Quidel by 162.7% in the third quarter. Great West Life Assurance Co. Can now owns 4,642 shares of the company’s stock valued at $204,000 after buying an additional 2,875 shares during the last quarter. Jane Street Group LLC acquired a new position in shares of Quidel in the third quarter valued at approximately $205,000. Legal & General Group Plc raised its position in shares of Quidel by 4.0% in the second quarter. Legal & General Group Plc now owns 7,209 shares of the company’s stock valued at $197,000 after buying an additional 278 shares during the last quarter. Finally, Russell Investments Group Ltd. acquired a new position in shares of Quidel in the second quarter valued at approximately $209,000. 92.67% of the stock is owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY NOTICE: “Insider Selling: Quidel Co. (QDEL) Director Sells 4,000 Shares of Stock” was originally posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece of content on another publication, it was illegally stolen and republished in violation of U.S. & international copyright & trademark law. The legal version of this piece of content can be accessed at https://www.thecerbatgem.com/2018/01/11/insider-selling-quidel-co-qdel-director-sells-4000-shares-of-stock.html.

About Quidel

Quidel Corporation is engaged in the development, manufacturing and marketing of diagnostic testing solutions. These diagnostic testing solutions are separated into four product categories: immunoassays, molecular assays, virology and specialty products. The Company sells its products directly to end users and distributors, in each case, for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, universities, retail clinics, pharmacies and wellness screening centers.

Insider Buying and Selling by Quarter for Quidel (NASDAQ:QDEL)

Receive News & Stock Ratings for Quidel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quidel and related stocks with our FREE daily email newsletter.